---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-072330"
form_type: "8-K"
ticker: "MOVE"
cik: "0001734750"
company_name: "Corvex, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:43:31.208295+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Movano Health reports Q3 net loss of $8.6M; progress on FDA submission and beta programs

## Summary
- Net loss of $8.6M ($0.26 diluted EPS) vs $5.2M ($0.16) in Q3 2021; no revenue.
- Cash and short-term investments $16.8M at Sept 30, down from $33.6M at Dec 31, 2021.
- Raised $1.9M via ATM facility in Q3; 33.5M shares outstanding.
- Plans to file for FDA clearance for heart rate and SpO2 in early 2023 after pivotal hypoxia study.
- Beta programs underway with Novant Health, Stanford, and two other partners; product launch expected H1 2023.

## SEC filing metadata
- accession: 0001213900-22-072330
- form_type: 8-K
- ticker: MOVE
- cik: 0001734750
- company_name: Corvex, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1734750/000121390022072330/0001213900-22-072330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1734750/000121390022072330/ea168495-8k_movanoinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-072330
- JSON: https://secwatch.observer/filing/0001213900-22-072330.json
- Plain text: https://secwatch.observer/filing/0001213900-22-072330.txt

## Key facts
- Earnings Releases
  Corvex, Inc. reported three months ending September 30, 2022 results: net income $8.6 million, EPS $(0.26) per basic and diluted share.
  - Period: three months ending September 30, 2022
  - Net income: $8.6 million
  - EPS: $(0.26) per basic and diluted share
  - Result: reported results
  source text: Movano Health reported a net loss attributable to common stockholders of $8.6 million, or a loss of $(0.26) per basic and diluted share, in the third quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1734750/000121390022072330/0001213900-22-072330-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.